

Receptor Implications

Adapted from An Antipsychotic Roundup: New Agents and Safety Updates

By Tammie Lee Demler, BS, PharmD, MBA, BCGP, BCPP

Receptor action	Potential clinical implications of receptor activity of APS*
D ₂ antagonism	Positive symptom efficacy High 5-HT _{2A} /D ₂ affinity ratio=reduced EPS (versus pure D ₂ antagonism) (-EPS, endocrine effects)
D ₂ partial agonism	Reduced positive symptoms, lowers risk of EPS
D ₃ antagonism	Reduced positive and negative symptoms also pro-cognitive and antidepressant effects
5-HT _{1A} antagonism	Reduced EPS and endocrine effects also antidepressant & anxiolytic effects
5-HT _{2A} antagonism	Reduced EPS and endocrine effects (- cardiometabolic effects)

Receptor action	Potential clinical implications of receptor activity of APS*
5-HT _{2c} antagonism	Antidepressant effects (- cardiometabolic effects)
5-HT ₇ antagonism	Reduced circadian rhythm dysfunction, reduced negative symptoms
α ₁ antagonism	Reduced nightmares; Postural hypotension, dizziness & sedation
H ₁ antagonism	Sedative/hypnotic effects (-cardiometabolic , weight gain and excessive sedation)
M ₁ antagonism	Anticholinergic side effects (ie: cognitive impairment)
M ₃ antagonism	Reduced EPS (-cardiometabolic, anticholinergic effects)
M ₄ agonism	clozapine only, increases hypersalivation